Pharma BD Deal Intelligence

Eli Lilly and Company / Alnara Pharmaceuticals

2010 · Acquisition/Merger · $380M · Complete

Announcement Sentiment

Neutral / mixed

Lilly to acquire Alnara for $180M upfront + up to $200M development/regulatory milestones. Adds Phase 3-ready protein therapeutic for pancreatic insufficiency.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Jul 02, 2010
Closed Jul 30, 2010
Deal value $380M
Deal type Acquisition/Merger
Therapeutic area Exocrine pancreatic insufficiency (cystic fibrosis)
Indications Exocrine pancreatic insufficiency (cystic fibrosis)
Key assets Liprotamase (pancreatic enzyme replacement)
Mechanism Recombinant pancreatic enzyme combination (lipase, protease, amylase)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals